BioAtla, Inc.

The company, BioAtla, Inc., is a clinical-stage biopharmaceutical company focused on developing novel antibody-based therapeutics for solid tumor cancers ¹. Its core business model revolves around its proprietary Conditionally Active Biologics (CAB) technology, which designs antibodies to selectively bind to tumor antigens in the acidic tumor microenvironment while remaining inactive in healthy tissue ². This approach aims to reduce on-target, off-tumor toxicity, a significant challenge in existing cancer therapies, and potentially improve the benefit-risk ratio for patients ³. The company generates revenue through collaboration and licensing agreements, as it currently has no products approved for commercial sale ⁴.

BioAtla's product pipeline includes several clinical-stage and preclinical candidates. BA3182 (CAB-EpCAM x CAB-CD3) is a bispecific antibody in a Phase 1 dose escalation study for advanced adenocarcinoma, which has shown a more than 100-fold improvement in therapeutic window compared to a non-CAB anti-EpCAM bispecific antibody in IND-enabling studies ⁵. Ozuriftamab vedotin (BA3021) is a CAB antibody drug conjugate (ADC) targeting ROR2, which has shown promising overall response rates in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) and is being planned for a Phase 3 trial ⁶. Mecbotamab vedotin (BA3011) is another CAB ADC targeting AXL, which has demonstrated promising long-term survival in heavily pre-treated mutated KRAS NSCLC patients in a Phase 2 study ⁷. Evalstotug (BA3071) is a CAB anti-CTLA-4 antibody that has completed Phase 1 and 2 studies as an immuno-oncology agent, showing promising efficacy with low-grade adverse events ⁸. Preclinical candidates include BA3361 (CAB-Nectin-4-ADC), for which an IND has been cleared ⁹, and BA3142 (CAB-B7-H3 x CAB-CD3), a dual-CAB T-cell engager ¹⁰.

For the fiscal year ended December 31, 2025, BioAtla reported a net loss of $59.6 million ¹¹, compared to a net loss of $69.8 million for the year ended December 31, 2024 ¹². As of December 31, 2025, the company had an accumulated deficit of $545.6 million ¹³ and approximately $7.1 million in cash and cash equivalents ¹⁴. The company's recurring losses from operations raise substantial doubt about its ability to continue as a going concern for the 12 months from the date its consolidated financial statements were issued ¹⁵.

The company has engaged in several significant operational developments and collaborations. In January 2022, BioAtla entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (BMS) for combination therapies using mecbotamab vedotin and ozuriftamab vedotin with Opdivo® (nivolumab) ¹⁶. In November 2021, the global co-development and collaboration agreement with BeOne Medicines, Ltd. for evalstotug was terminated, with BioAtla assuming responsibility for its development and commercialization ¹⁷. An amended and restated exclusive rights agreement with Himalaya Therapeutics SEZC in January 2020 granted them exclusive licenses for 10 CAB-antibodies in certain Asian territories and a CAB-HER2-bispecific-antibody worldwide, with potential payments up to $77.5 million in upfront and milestones ¹⁸. In September 2024, BioAtla licensed BA3362 (renamed CT-202) to Context Therapeutics Inc., with potential aggregate payments of up to $133.5 million, including an upfront cash payment and potential milestones, as well as tiered mid-single digit to low double-digit royalties on future net sales ¹⁹. In December 2025, an investment agreement with Inversagen AI, LLC was entered into for the sale of common units in a subsidiary (BA 3021 SPV LLC) for an aggregate of $40 million, intended to fund general operating and clinical trial expenses for ozuriftamab vedotin, though the transaction has not closed and is being re-evaluated ²⁰. On March 2, 2026, the company announced a formal process to explore strategic options to maximize shareholder value, including asset sales, licensing, partnerships, or other corporate transactions, and implemented a workforce reduction of approximately 70% ²¹.

BioAtla has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships, or other corporate transactions ²². The company does not intend to provide updates until its Board of Directors approves a specific action or determines disclosure is appropriate or required ²³. In connection with this strategic evaluation, BioAtla is re-evaluating the timing and scope of its clinical development programs ²⁴.

Specifically, the company is re-evaluating the appropriate timeline and pacing of additional enrollment in the Phase 1 study of BA3182 (CAB-EpCAM x CAB-CD3) ²⁵. For ozuriftamab vedotin (BA3021), the timeline to commence a Phase 3 study for patients with OPSCC who have previously received anti-PD-(L)1 therapy and platinum-containing therapy is also being re-evaluated ²⁶. The FDA has provided guidance that 1.8 mg/kg of ozuriftamab vedotin delivered every other week satisfies dose optimization requirements for this planned Phase 3 trial ²⁷.

BioAtla plans to continue leveraging its CAB platform, which has shown in preclinical experiments, including for BA3182, that CAB bispecific molecules meet or exceed the activity of conventional bispecifics and reduce systemic activation of potentially fatal immune responses ²⁸. The company is also developing a next-generation CAB-ADC platform that replaces the traditional peptide linker with a novel sugar-based linker to deliver the MMAE payload, expected to further reduce off-target, off-tumor toxicity and expand the therapeutic window ²⁹.

The company's operational outlook includes cost-containment measures, such as a workforce reduction of approximately 70%, implemented in connection with the evaluation of strategic options ³⁰. These measures are intended to better align resources with near-term priorities and preserve capital ³¹.

Regarding capital allocation, BioAtla's existing cash and cash equivalents of approximately $7.1 million as of December 31, 2025, are estimated to fund operations only past the first half of 2026 ³². The company expects to finance future cash needs through equity or debt financings, strategic collaborations, or a combination of these approaches ³³. The investment agreement with Inversagen AI, LLC for an aggregate of $40 million for the SPV common units, intended to advance Oz-V in the Phase 3 Study, has not closed and is being re-evaluated for potential restructuring pending the outcome of the strategic process ³⁴.

The company explicitly flagged that there can be no assurance that the strategic process will result in any agreements or transactions ³⁵. Furthermore, there can be no assurances that clinical development of its programs will not be limited or delayed pending the outcome of the strategic process ³⁶. The company's ability to raise additional funds may be adversely impacted by negative global economic conditions and any disruptions to and volatility in the credit and financial markets ³⁷. The recently enacted Inflation Reduction Act of 2022 (IRA) will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products, including requiring HHS to directly negotiate selling prices for certain drugs and biologics and imposing rebates on drugs whose prices increase faster than inflation ³⁸. The One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, is estimated to reduce Medicaid coverage for 7.8 million adults by 2034 and increase the number of uninsured Americans by 3.6 million by 2034, which could reduce demand for the company's products ³⁹.

BioAtla faces several material risks, including substantial uncertainty regarding its ability to continue as a going concern, as its cash and cash equivalents of approximately $7.1 million ⁴⁰ as of December 31, 2025, are estimated to fund operations only past the first half of 2026 ⁴¹. The company is currently not in compliance with Nasdaq's continued listing requirements, specifically the Minimum Bid Price Requirement and the Minimum Stockholders' Equity Requirement, and its common stock could be delisted ⁴². The formal process initiated to explore strategic options may not result in any agreements or transactions, and if a strategic transaction is not completed, the company may be forced to cease operations or file for bankruptcy protection ⁴³. Operational risks include the potential for product candidates to fail in development or suffer delays, with results from early-stage clinical trials not being predictive of late-stage outcomes ⁴⁴. The company's reliance on its novel CAB technology platform means any setbacks could have a detrimental impact on all product candidates ⁴⁵. There is a significant risk of product liability inherent in the development and testing of product candidates ⁴⁶. The company faces intense competition from other biopharmaceutical companies developing cancer treatments, including novel approaches like CAR-T, ADCs, and prodrug biologics ⁴⁷. Regulatory risks include the potential inability to obtain U.S. or foreign regulatory approval, the possibility that accelerated approval pathways may not be granted or maintained, and ongoing regulatory obligations and review post-approval ⁴⁸. Healthcare legislative reforms, such as the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act, could negatively impact pricing, reimbursement, and market demand for products ⁴⁹. Relationships with healthcare professionals and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws, which could lead to significant penalties ⁵⁰. The company's dependence on third parties for preclinical and clinical trials and manufacturing increases the risk of delays or insufficient supplies ⁵¹. Intellectual property risks include the potential inability to obtain, maintain, and protect patent rights, challenges to inventorship or ownership, and costly litigation ⁵². A portion of the company's research and development activities take place in China, exposing it to uncertainties regarding Chinese laws, trade wars, and political unrest ⁵³. The company is also vulnerable to cybersecurity threats, including attacks and data breaches, which could disrupt operations and lead to significant liabilities ⁵⁴.

Management's message to shareholders emphasizes the initiation of a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships, or other corporate transactions ⁵⁵. This process is accompanied by a workforce reduction of approximately 70% and other cost-containment measures to align resources with near-term priorities and preserve capital ⁵⁶. Management explicitly states that there can be no assurance that this strategic process will result in any agreements or transactions ⁵⁷. The company is re-evaluating the timing and scope of its clinical development programs, including the appropriate timeline and pacing of additional enrollment in the Phase 1 study of BA3182 and the timeline to commence a Phase 3 study for ozuriftamab vedotin ⁵⁸. Management's strategic priorities include entering into collaborations to maximize the value of its platform and pipeline, continued prioritization of its lead product candidates (BA3182, Ozuriftamab vedotin, Mecbotamab vedotin, Evalstotug), continuing to leverage its CAB platform, and maintaining and leveraging its intellectual property portfolio ⁵⁹.